Done sou Salè H1B

Akèy › Anplwayè › Abbvie Endocrinology Inc.

Abbvie Endocrinology Inc.: Salè H-1B ak pajon

Abbvie Endocrinology Inc. depoze 3 aplikasyon kondisyon travay pou visa H-1B ak visa ki gen rapò nan ane fiskal 2023–2026; sètifye: 3. Medyèn salè yo ofri a: $159,000.

Demann (LCA)3
Certifye3
Adrès anplwayèNorth Chicago, IL
Anplwayè H-1B depannNon
Salè medyan ofri$159,000
Mwatye salè yo$157,000–$164,000
10yèm–90yèm pousantaj$155,800–$167,000

Èske Abbvie Endocrinology Inc. pajone visa H-1B?

Abbvie Endocrinology Inc. depoze 3 aplikasyon kondisyon travay nan ane fiskal 2023–2026, dènye a soumèt sou Sep 8, 2025. Yon LCA se premye etap yon demann H-1B, konsa anplwayè a pajone oswa prepare pou pajone travayè H-1B; li pa garanti pajon pou okenn travay espesifik. Tcheke lis travay pwòp anplwayè a.

Salè pa tit travay

Tit travayLCASalè medyan
Senior Manager, IT Operations1$169,000
Business System Consultant - Pharmacy Management Systems1$159,000
Solution Architect1$155,000

Aplikasyon pa ane fiskal

Ane fiskalLCASalè medyan
FY20241$169,000
FY20252$157,000

Nivo salè prevanlan

Depatman Travay la etabli kat nivo salè prevanlan pou chak okipasyon ak zòn, soti nan Nivo I (antre) rive nan Nivo IV (plen kompetans). Anplwayè a chwazi nivo ki koresponn ak kondisyon travay la.

Kote travay yo ye

Okipasyon

Dènye aplikasyon yo

Tit travaySalè bazKoteSoumètDat kòmansmanEstati
Solution Architect$155,000–$175,000
Nivo IV
North Chicago, ILSep 8, 2025Sep 17, 2025Certifye
Business System Consultant - Pharmacy Management Systems$159,000–$179,000
Nivo IV
North Chicago, ILJan 2, 2025Jan 10, 2025Certifye
Senior Manager, IT Operations$169,000–$189,000
Nivo III
North Chicago, ILApr 5, 2024Apr 16, 2024Certifye

Salè yo se fen ki pi ba nan salè yo ofri sou chak aplikasyon, konvèti nan yon montan anyèl; estatistik yo itilize sèlman aplikasyon tan plen sètifye. Yon LCA pa yon apwobasyon visa epi yon sèl LCA ka kouvri plizyè pozisyon. Sous: Depatman Travay Etazini, Done Divulgasyon LCA OFLC, ane fiskal 2023–2026 (dènye desizyon Jun 30, 2026).